Physician profile
John B Madden
NPI 1790795276
$19,982.82
in general payments reported to CMS, 2019-2025
54 companies · $2,945 in 2025
The $2,945 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,905 · 2020: $2,068 · 2021: $3,398 · 2022: $3,105 · 2023: $2,794 · 2024: $2,767 · 2025: $2,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,506.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,485.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,388.19 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,044.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,608.38 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,187.63 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $1,059.81 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $932.76 | 2019-2025 | Zepbound, Mounjaro, Kisunla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $825.32 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $737.82 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Janssen Pharmaceuticals, INC | $547.10 | 2019-2023 | Spravato |
| Kowa Pharmaceuticals America, INC. | $486.81 | 2019-2025 | Seglentis, Zoryve, Livalo |
| Bayer Healthcare Pharmaceuticals INC. | $380.75 | 2021-2025 | |
| Astellas Pharma US INC | $357.46 | 2019-2024 | Myrbetriq |
| Allergan, INC. | $324.19 | 2019-2021 | |
| Lundbeck LLC | $321.02 | 2023-2025 | Rexulti, Vyepti |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $317.20 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.57 | 2019-2025 | Synjardy, Jardiance, Ofev |
| Eisai INC. | $303.29 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $275.38 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $221.19 | 2024-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $220.35 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $220.16 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $216.62 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $207.46 | 2021-2024 | Unithroid |
| Biohaven Pharmaceuticals, INC. | $183.24 | 2021 | |
| Merck Sharp & Dohme LLC | $175.05 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Abbott Laboratories | $170.48 | 2021-2025 | Proclaim |
| Phathom Pharmaceuticals, INC. | $152.68 | 2024-2025 | Voquezna |
| Dexcom, INC. | $118.98 | 2023-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $115.53 | 2022-2025 | |
| Tris Pharma INC | $111.88 | 2023-2025 | Dyanavel Xr |
| Amarin Pharma, INC. | $100.82 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $94.57 | 2023 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $93.70 | 2021 | |
| Esperion Therapeutics, INC. | $93.38 | 2020-2021 | |
| Axsome Therapeutics, INC. | $72.71 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $51.47 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $51.07 | 2021 | |
| Exact Sciences Corporation | $49.29 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $39.18 | 2024 | |
| Inari Medical, INC. | $35.15 | 2024-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Jazz Pharmaceuticals INC. | $34.87 | 2021-2022 | |
| Inspire Medical Systems, INC. | $33.43 | 2023-2025 | Inspire |
| Genentech USA, INC. | $31.31 | 2019 | |
| Idorsia Pharmaceuticals US INC | $31.28 | 2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $29.31 | 2024 | Hetlioz, Fanapt |
| Arbor Pharmaceuticals, INC. | $27.10 | 2019 | |
| Alnylam Pharmaceuticals INC. | $26.58 | 2023 | Oxlumo, Givlaari |
| Otsuka America Pharmaceutical, INC. | $19.38 | 2024 | Rexulti |
| Halozyme INC | $15.42 | 2023 | |
| Medtronic, INC. | $13.39 | 2023 | Intellis Adaptivestim |
| Circassia INC. | $12.39 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $10.94 | 2019 | |
| Corium, LLC | $8.76 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Madden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.